Jump to content

Drilldown: Medicines

Pharmacopedia
BrowseCategoriesLog in

Choose a table:


Medicines > generic : 2-AI or 2C-B or Norethindrone (norethisterone outside US)

Use the filters below to narrow your results.

generic: (Click arrow to add another value)
brand:
None (1) · Aygestin (5 mg, Rx); Camila, Errin, Heather, Jolivette, Nor-QD, Ortho Micronor, Sharobel (0.35 mg POPs); component of many COCs (1) · Nexus, Eroxan (historical, late-1980s through mid-1990s) (1)
classes:
2C-x series (1) · Phenethylamine (1) · Psychedelic (1) · Research material (1) · Stimulant (1) · [[:Category:Hormonal_contraceptives|Hormonal contraceptive]] (1) · [[:Category:Progestins|Progestin (synthetic progestogen)]] (1) · [[:Category:Sex_hormones|Sex hormone]] (1)
mechanism:
5-HT2A partial agonist (1) · Alpha-methylated amphetamine analogue; norepinephrine releasing agent (1) · '"`UNIQ--vote-000013EE-QINU`"' Higher-dose Aygestin (5 mg) achieves more reliable ovulation suppression and is used for endometriosis and DUB. POP requires strict daily timing because the 24-hour cervical-mucus effect window is narrower than COC'"`UNIQ--ref-000013EF-QINU`"'. (1)
uses:
None (2) · '"`UNIQ--vote-000013F0-QINU`"', '"`UNIQ--vote-000013F1-QINU`"', '"`UNIQ--vote-000013F2-QINU`"', '"`UNIQ--vote-000013F3-QINU`"', '"`UNIQ--vote-000013F4-QINU`"' (1)
starting dose:
None (2) · POP: 0.35 mg PO daily continuously (no placebo week); high-dose 5 mg Aygestin for amenorrhea/endometriosis 5-10 mg/d (1)
preparations:
None (2) · 0.35 mg POP tablets; 5 mg tablets (Aygestin); component of COCs and combination HRT (1)
fda max:
None (2) · Indication-specific (1)
routes:
None (1) · insufflated (1) · Oral (2) · PR (1)
onset:
None (1) · 45-75 min (oral) (1) · Contraception within 48 hours of starting (POP); endometrial effects days (1)
duration:
None (1) · 4-8 h (1) · ~24 hours per dose (strict timing required for POP — within 3-hour window each day) (1)
halflife:
None (1) · Not well characterized (1) · ~8 hours'"`UNIQ--ref-000013F5-QINU`"' (1)
bioavailability:
None (1) · Not well characterized (1) · ~65% (oral)'"`UNIQ--ref-000013F6-QINU`"' (1)
pregnancy:
None (1) · Contraindicated in known pregnancy (Aygestin); the 0.35 mg POP is not teratogenic and does not need to be discontinued before conception planning.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Not established (1)
legal:
None (1) · [[USLegal:DEA Schedule I|Schedule I]] (United States) (1) · [[USLegal:Prescription only|Rx-only]] in US (note: norgestrel 0.075 mg POP is now OTC as Opill since 2023, but norethindrone POP remains Rx) (1)

Showing below up to 3 results in range #1 to #3.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

2


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"